Deep Human Biology Learning (DHBL) is a unique approach to oncology & neurology research. Through cross-disciplinary collaboration, drug discovery is accelerated, leading to faster development of ...

LEADS® leverages system-level readouts to enable unbiased discovery while providing deep mechanistic insight. Sinopia has generated the largest metabolomics dataset characterizing a small-molecule ...

In the pharmaceutical discovery process, understanding a drug’s residence time—the duration a molecule remains bound to its ...

AlphaFold arrived as a technical moonshot that suddenly made protein structures feel like software rather than secrets of ...

Insilico Medicine (3696.HK), a clinical-stage drug discovery and development company driven by generative artificial intelligence (AI), is successfully listed on the Hong Kong Stock Exchange today, ...

In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...

In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...

Frey is founder and chief innovation officer of Deep Genomics. In a time of relentless AI hype and mounting global economic uncertainty, the real winners will be those who think long-term. One of the ...

Ola Engkvist is the Executive Director and Head of Molecular AI in Discovery Sciences within R&D at AstraZeneca (headquartered in Cambridge, UK). His team harnesses advanced computational technologies ...

AI therapeutics company built on causal biology, today announced the publication of research in Nature Communications validating its POSH (Pooled Optical Screening in Human cells) platform. The study ...